VZ-103
dry age-related macular degeneration (dry AMD)
PreclinicalActive
Key Facts
Indication
dry age-related macular degeneration (dry AMD)
Phase
Preclinical
Status
Active
Company
About Vzarii Therapeutics
Vzarii Therapeutics is an early-stage biotech focused on developing gene therapies for neurodegenerative diseases by addressing underlying mitochondrial dysfunction. Spun out from pioneering research at Trinity College Dublin, the company is currently in the preclinical stage with a platform technology applicable to multiple conditions, including dry AMD, glaucoma, Alzheimer's, Parkinson's, and Motor Neuron Disease. Its initial focus is on advancing VZ-103 for dry AMD, a major unmet medical need with a significant market opportunity. The company represents a specialized player in the growing field of mitochondrial-targeted gene therapies.
View full company profile